AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab), a groundbreaking therapy for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) following two or more prior treatments. This approval marks a significant milestone as TEPKINLY becomes the first and only […]
Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the 2023 American Society of Hematology (ASH) Annual Meeting. This trial, part of a global, multicenter Phase 2 study, evaluates the efficacy of Breyanzi (lisocabtagene maraleucel, liso-cel) in patients with relapsed or refractory follicular lymphoma (FL). TRANSCEND FL: […]
Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US Food and Drug Administration (FDA) for Lunsumio (mosunetuzumab-axgb) for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) in adults, subjected to two or more treatments for their cancer. Lunsumio is a CD20xCD3 T-cell engaging bispecific […]
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed on Nasdaq, is focused on developing and delivering therapies against novel epigenetic targets for patients with different types of cancer. Through the deal, Ipsen gets access to Tazverik (tazemetostat), the […]
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion in an all-cash deal. The portfolio of Trillium Therapeutics has biologics that have been designed to boost the ability of patients’ innate immune systems for detecting and killing cancer cells. […]
Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). The goal of the study being held in China is to assess the efficacy and safety of parsaclisib in patients having recurrent or refractory follicular lymphoma or marginal zone lymphoma […]
Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular lymphoma (FL). As per the new drug application (NDA) that has been accepted by the FDA, the Massachusetts-based biopharma company is seeking the accelerated approval of the methyltransferase inhibitor for […]
Nordic Nanovector has commenced the dosing of the first patient in its Phase 1b clinical trial, dubbed Archer-1, which aims to evaluate the combination of its investigational lymphoma drug Betalutin (177Lu-satetraxetan-lilotomab) with Roche’s rituximab (RTX) as a second-line treatment for follicular lymphoma (2L FL). This trial is a critical step in exploring novel treatments for […]
Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed to assess the efficacy of Betalutin (lilotomab), an innovative anti-CD37 antibody, in treating third-line (3L) follicular lymphoma patients who have previously failed anti-CD20 therapies. PARADIGME Trial Marks a Significant Milestone […]